PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/505, A61P 3/06

A1

(11) International Publication Number: WO 00/45817

(43) International Publication Date: 10 August 2000 (10.08.00)

(21) International Application Number: PCT/GB00/00278

(22) International Filing Date: 1 February 2000 (01.02.00)

(30) Priority Data:

9902593.4	6 February 1999 (06.02.99)	GB
9921063.5	8 September 1999 (08.09.99)	GB
9921064.3	8 September 1999 (08.09.99)	GB

(71) Applicants *(for all designated States except US)*: ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). SHIONOGI & CO LTD [JP/JP]; Doshomachi 3–chome, Chuo–ku, Osaka 541–0045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: RAZA, Ali [GB/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850–5437 (US). PEARS, John, Stuart [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). HUTCHINSON, Howard, Gerard [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850–5437 (US). SCHNECK, Dennis [US/US]; 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850–5437 (US). BABA, . Takahiko [JP/JP]; Shionogi & Co Ltd, 1–1, Futabacho 3–chome, Toyonaka–shi, Osaka 561–0825 (JP). TOUCHI, Akira [JP/JP]; Shionogi & Co Ltd, 1–1, Futabacho 3–chome, Toyonaka–shi, Osaka 561–0825 (JP). YAMAGUCHI, Yoshitaka [JP/JP]; Shionogi & Co Ltd, 1–1, Futabacho 3–chome, Toyonaka–shi, Osaka 561–0825 (JP).

(74) Agent: BROWN, Andrew, Stephen; Global Intellectual Property, AstraZeneca Uk Limited, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: DRUG COMBINATIONS COMPRISING (E) –7 – [4 –(4 –FLUOROPHENYL) –6 – ISOPROPYL –2 – [METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN –5 –YL] (3R,5S) –3,5 – DIHYDROXYHEPT –6 – ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4

(57) Abstract

The invention concerns safe non–interacting drug combinations of a 3–hydroxy –3– methylglutaryl coenzyme A (HMG–CoA) reductase inhibitor, which is (E)–7– [4–(4–fluorophenyl) –6– isopropyl –2– [methyl (methylsulfonyl) amino] pyrimidin–5–yl] (3R,5S)–3,5–dihydroxyhept –6–enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.